A Comprehensive Review on the State of the Art of Breast Cancers in Italy


Cite item

Full Text

Abstract

Breast cancer (BC) currently represents one of the most prevalent cancers among women worldwide and the leading cause of cancer death among women, also negatively affecting the quality of life (QoL) in patients. Over the past two decades, BC research has led to extraordinary advances in our understanding of the disease, resulting in more effective treatments. However, its occurrence is still increasing. Several new treatments are now under development worldwide, but they are not devoid of wellknown side effects, and a great number of patients develop endocrine resistance. Nevertheless, the design and synthesis of more suitable strategies and new drugs to treat breast cancers, overcome resistance and side effects, and obtain better therapeutic outcomes are needed. In this review, we summarize the therapies and the clinical studies currently ongoing in Italy for the treatment of BCs, mainly HER2+ MBC, HER2-low MBC, and TNBC, focusing on the most recent ones, also in consideration of diverse facets, including some aspects related to QoL. Finally, some studies related to the usefulness of physical activity in BC will be cited.

About the authors

Domenico Iacopetta

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria

Email: info@benthamscience.net

Jessica Ceramella

Department of Pharmacy, Health and Nutritional Sciences,, University of Calabria

Email: info@benthamscience.net

Alessia Catalano

Department of Pharmacy-Drug Sciences,, University of Bari "Aldo Moro"

Author for correspondence.
Email: info@benthamscience.net

Camillo Rosano

U.O. Proteomica e Spettrometria di Massa,, IRCCS Ospedale Policlinico San Martino

Email: info@benthamscience.net

Annaluisa Mariconda

Department of Science, University of Basilicata

Email: info@benthamscience.net

Federica Giuzio

Department of Science, University of Basilicata

Email: info@benthamscience.net

Daniela Bonofiglio

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria

Email: info@benthamscience.net

Carmela Saturnino

Department of Science, University of Basilicata

Email: info@benthamscience.net

Pasquale Longo

Department of Chemistry and Biology, University of Salerno

Email: info@benthamscience.net

Maria Sinicropi

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria

Email: info@benthamscience.net

References

  1. Siegel, R.L.; Miller, K.D.; Wagle, N.S.; Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin., 2023, 73(1), 17-48. doi: 10.3322/caac.21763 PMID: 36633525
  2. Iacopetta, D.; Ceramella, J.; Baldino, N.; Sinicropi, M.; Catalano, A. Targeting breast cancer: An overlook on current strategies. Int. J. Mol. Sci., 2023, 24(4), 3643. doi: 10.3390/ijms24043643 PMID: 36835056
  3. Tarantino, P.; Viale, G.; Press, M.F.; Hu, X.; Penault-Llorca, F.; Bardia, A.; Batistatou, A.; Burstein, H.J.; Carey, L.A.; Cortes, J.; Denkert, C.; Diéras, V.; Jacot, W.; Koutras, A.K.; Lebeau, A.; Loibl, S.; Modi, S.; Mosele, M.F.; Provenzano, E.; Pruneri, G.; Reis-Filho, J.S.; Rojo, F.; Salgado, R.; Schmid, P.; Schnitt, S.J.; Tolaney, S.M.; Trapani, D.; Vincent-Salomon, A.; Wolff, A.C.; Pentheroudakis, G.; André, F.; Curigliano, G. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann. Oncol., 2023, 34(8), 645-659. doi: 10.1016/j.annonc.2023.05.008 PMID: 37269905
  4. Agostinetto, E.; Rediti, M.; Fimereli, D.; Debien, V.; Piccart, M.; Aftimos, P.; Sotiriou, C.; de Azambuja, E. HER2-low breast cancer: Molecular characteristics and prognosis. Cancers, 2021, 13(11), 2824. doi: 10.3390/cancers13112824 PMID: 34198891
  5. Zhang, H.; Peng, Y. Current biological, pathological and clinical landscape of HER2-low breast cancer. Cancers, 2022, 15(1), 126. doi: 10.3390/cancers15010126 PMID: 36612123
  6. D’Arienzo, A.; Verrazzo, A.; Pagliuca, M.; Napolitano, F.; Parola, S.; Viggiani, M.; Caputo, R.; Puglisi, F.; Giuliano, M.; Del Mastro, L.; Arpino, G.; De Laurentiis, M.; Montemurro, F. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations. EClinicalMedicine, 2023, 62, 102113. doi: 10.1016/j.eclinm.2023.102113 PMID: 37554126
  7. Shyam Sunder, S.; Sharma, U.C.; Pokharel, S. Adverse effects of tyrosine kinase inhibitors in cancer therapy: Pathophysiology, mechanisms and clinical management. Signal Transduct. Target. Ther., 2023, 8(1), 262. doi: 10.1038/s41392-023-01469-6 PMID: 37414756
  8. Tarantino, P.; Corti, C.; Schmid, P.; Cortes, J.; Mittendorf, E.A.; Rugo, H.; Tolaney, S.M.; Bianchini, G.; Andrè, F.; Curigliano, G. Immunotherapy for early triple negative breast cancer: Research agenda for the next decade. NPJ Breast Cancer, 2022, 8(1), 23. doi: 10.1038/s41523-022-00386-1 PMID: 35181659
  9. Heins, M.J.; de Ligt, K.M.; Verloop, J.; Siesling, S.; Korevaar, J.C.; Berendsen, A.; Brandenbarg, D.; Dassen, A.; Jager, A.; Hugtenburg, J.; Weele, G. Adverse health effects after breast cancer up to 14 years after diagnosis. Breast, 2022, 61, 22-28. doi: 10.1016/j.breast.2021.12.001 PMID: 34891036
  10. Boszkiewicz, K.; Piwowar, A.; Petryszyn, P. Aromatase inhibitors and risk of metabolic and cardiovascular adverse effects in breast cancer patients - A systematic review and meta-analysis. J. Clin. Med., 2022, 11(11), 3133. doi: 10.3390/jcm11113133 PMID: 35683517
  11. Lemij, A.A.; de Glas, N.A.; Derks, M.G.M.; Bastiaannet, E.; Merkus, J.W.S.; Lans, T.E.; van der Pol, C.C.; van Dalen, T.; Vulink, A.J.E.; van Gerven, L.; Guicherit, O.R.; Linthorst-Niers, E.M.H.; van den Bos, F.; Kroep, J.R.; Liefers, G.J.; Portielje, J.E.A. Discontinuation of adjuvant endocrine therapy and impact on quality of life and functional status in older patients with breast cancer. Breast Cancer Res. Treat., 2022, 193(3), 567-577. doi: 10.1007/s10549-022-06583-7 PMID: 35441273
  12. Keane, D.; Phillips, G.; Mitchell, N.; Connolly, R.M.; Hegarty, J. Improving quality of life and symptom experience in patients with metastatic breast cancer: A systematic review of supportive care interventions. Psychooncology, 2023, 32(8), 1192-1207. doi: 10.1002/pon.6183 PMID: 37434307
  13. Sun, H.; Xu, J.; Dai, S.; Ma, Y.; Sun, T. Breast cancer brain metastasis: Current evidence and future directions. Cancer Med., 2023, 12(2), 1007-1024. doi: 10.1002/cam4.5021 PMID: 35822637
  14. Farahani, M.K.; Gharibshahian, M.; Rezvani, A.; Vaez, A. Breast cancer brain metastasis: From etiology to state-of-the-art modeling. J. Biol. Eng., 2023, 17(1), 41. doi: 10.1186/s13036-023-00352-w PMID: 37386445
  15. Vega Cano, K.S.; Marmolejo Castañeda, D.H.; Escrivá-de-Romaní, S.; Saura, C. Systemic therapy for HER2-positive metastatic breast cancer: Current and future trends. Cancers, 2022, 15(1), 51. doi: 10.3390/cancers15010051 PMID: 36612047
  16. Simion, L.; Augustin, I.G.; Volovat, S.R.; Froicu, E.M.; Schenker, M.; Mazilu, L.; Nitipir, C.; Zivari, M.; Volovat, C.; Alecu, M.; Tanase, B.; Cirimbei, C.; Luca, D.C.; Stanculeanu, D.L.; Zob, D.L. HER2 positive breast cancer therapy - A challenging and continuously moving pathway – A narrative literature review. Arch Breast Cancer., 2022, 10(1), 15-25. doi: 10.32768/abc.202310115-25
  17. von Arx, C.; De Placido, P.; Caltavituro, A.; Di Rienzo, R.; Buonaiuto, R.; De Laurentiis, M.; Arpino, G.; Puglisi, F.; Giuliano, M.; Del Mastro, L. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer. Cancer Treat. Rev., 2023, 113, 102500. doi: 10.1016/j.ctrv.2022.102500 PMID: 36587473
  18. Gion, M.; Trapani, D.; Cortés, A.; Valenza, C.; Lin, N.; Cortés, J.; Curigliano, G. Systemic therapy for HER2-positive metastatic breast cancer: Moving into a new era. Am. Soc. Clin. Oncol. Educ. Book, 2022, 42(42), 82-92. doi: 10.1200/EDBK_351222 PMID: 35671434
  19. Agostinetto, E.; Montemurro, F.; Puglisi, F.; Criscitiello, C.; Bianchini, G.; Del Mastro, L.; Introna, M.; Tondini, C.; Santoro, A.; Zambelli, A. Immunotherapy for HER2-positive breast cancer: Clinical evidence and future perspectives. Cancers, 2022, 14(9), 2136. doi: 10.3390/cancers14092136 PMID: 35565264
  20. Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med., 2007, 357(1), 39-51. doi: 10.1056/NEJMra043186 PMID: 17611206
  21. Guidance for industry: pathological complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. Food and Drug Administration, 2014, Available from: https://www.fda.gov/downloads/drugs/guidances/ucm305501.pdf
  22. Howie, L.J.; Scher, N.S.; Amiri-Kordestani, L.; Zhang, L.; King-Kallimanis, B.L.; Choudhry, Y.; Schroeder, J.; Goldberg, K.B.; Kluetz, P.G.; Ibrahim, A.; Sridhara, R.; Blumenthal, G.M.; Pazdur, R.; Beaver, J.A. FDA approval summary: Pertuzumab for adjuvant treatment of HER2-positive early breast cancer. Clin. Cancer Res., 2019, 25(10), 2949-2955. doi: 10.1158/1078-0432.CCR-18-3003 PMID: 30552112
  23. Krop, I.E.; Kim, S.B.; Martin, A.G.; LoRusso, P.M.; Ferrero, J.M.; Badovinac-Crnjevic, T.; Hoersch, S.; Smitt, M.; Wildiers, H. Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): Final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol., 2017, 18(6), 743-754. doi: 10.1016/S1470-2045(17)30313-3 PMID: 28526538
  24. Baselga, J.; Lewis Phillips, G.D.; Verma, S.; Ro, J.; Huober, J.; Guardino, A.E.; Samant, M.K.; Olsen, S.; de Haas, S.L.; Pegram, M.D. Relationship between tumor biomarkers and efficacy in EMILIA, a phase III study of trastuzumab emtansine in HER2-positive metastatic breast cancer. Clin. Cancer Res., 2016, 22(15), 3755-3763. doi: 10.1158/1078-0432.CCR-15-2499 PMID: 26920887
  25. Diéras, V.; Miles, D.; Verma, S.; Pegram, M.; Welslau, M.; Baselga, J.; Krop, I.E.; Blackwell, K.; Hoersch, S.; Xu, J.; Green, M.; Gianni, L. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): A descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol., 2017, 18(6), 732-742. doi: 10.1016/S1470-2045(17)30312-1 PMID: 28526536
  26. Cortés, J.; Kim, S.B.; Chung, W.P.; Im, S.A.; Park, Y.H.; Hegg, R.; Kim, M.H.; Tseng, L.M.; Petry, V.; Chung, C.F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Huang, C.S.; Kim, J.H.; Chiu, J.W.Y.; Pedrini, J.L.; Lee, C.; Liu, Y.; Cathcart, J.; Bako, E.; Verma, S.; Hurvitz, S.A. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N. Engl. J. Med., 2022, 386(12), 1143-1154. doi: 10.1056/NEJMoa2115022 PMID: 35320644
  27. Hurvitz, S.A.; Hegg, R.; Chung, W-P.; Im, S.A.; Jacot, W.; Ganju, V. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet, 2022, 401, 105-117.
  28. Perez, E.A.; Barrios, C.; Eiermann, W.; Toi, M.; Im, Y.H.; Conte, P.; Martin, M.; Pienkowski, T.; Pivot, X.B.; Burris, H.A., III; Petersen, J.A.; De Haas, S.; Hoersch, S.; Patre, M.; Ellis, P.A. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE. Cancer, 2019, 125(22), 3974-3984. doi: 10.1002/cncr.32392 PMID: 31318460
  29. Yuan, Y.; Liu, X.; Cai, Y.; Li, W. Pyrotinib versus lapatinib therapy for HER2 positive metastatic breast cancer patients after first-line treatment failure: A meta-analysis and systematic review. PLoS One, 2023, 18(1), e0279775. doi: 10.1371/journal.pone.0279775 PMID: 36602979
  30. Saura, C.; Oliveira, M.; Feng, Y.H.; Dai, M.S.; Chen, S.W.; Hurvitz, S.A.; Kim, S.B.; Moy, B.; Delaloge, S.; Gradishar, W.; Masuda, N.; Palacova, M.; Trudeau, M.E.; Mattson, J.; Yap, Y.S.; Hou, M.F.; De Laurentiis, M.; Yeh, Y.M.; Chang, H.T.; Yau, T.; Wildiers, H.; Haley, B.; Fagnani, D.; Lu, Y.S.; Crown, J.; Lin, J.; Takahashi, M.; Takano, T.; Yamaguchi, M.; Fujii, T.; Yao, B.; Bebchuk, J.; Keyvanjah, K.; Bryce, R.; Brufsky, A. Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2- positive metastatic breast cancer previously treated with ≥ 2 HER2- directed regimens: Phase III NALA trial. J. Clin. Oncol., 2020, 38(27), 3138-3149. doi: 10.1200/JCO.20.00147 PMID: 32678716
  31. Alasmari, M.M. A review of margetuximab-based therapies in patients with HER2-positive metastatic breast cancer. Cancers, 2022, 15(1), 38. doi: 10.3390/cancers15010038 PMID: 36612034
  32. Rugo, H.S.; Im, S.A.; Cardoso, F.; Cortés, J.; Curigliano, G.; Musolino, A.; Pegram, M.D.; Wright, G.S.; Saura, C.; Escrivá-de-Romaní, S.; De Laurentiis, M.; Levy, C.; Brown-Glaberman, U.; Ferrero, J.M.; de Boer, M.; Kim, S.B.; Petráková, K.; Yardley, D.A.; Freedman, O.; Jakobsen, E.H.; Kaufman, B.; Yerushalmi, R.; Fasching, P.A.; Nordstrom, J.L.; Bonvini, E.; Koenig, S.; Edlich, S.; Hong, S.; Rock, E.P.; Gradishar, W.J. Efficacy of margetuximab vs. Trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: A phase 3 randomized clinical trial. JAMA Oncol., 2021, 7(4), 573-584. doi: 10.1001/jamaoncol.2020.7932 PMID: 33480963
  33. Wynn, C.S.; Tang, S.C. Anti-HER2 therapy in metastatic breast cancer: Many choices and future directions. Cancer Metastasis Rev., 2022, 41(1), 193-209. doi: 10.1007/s10555-022-10021-x PMID: 35142964
  34. Piezzo, M.; D’Aniello, R.; Avallone, I.; Barba, B.; Cianniello, D.; Cocco, S.; D’Avino, A.; Di Gioia, G.; Di Lauro, V.; Fusco, G.; Piscitelli, R.; von Arx, C.; De Laurentiis, M.; Maiolino, P. Uptake of trastuzumab biosimilars for the treatment of HER2-positive breast cancer: A real-world experience from a cancer center. Pharmaceutics, 2021, 13(5), 684. doi: 10.3390/pharmaceutics13050684 PMID: 34068626
  35. The selection and use of essential medicines: Report of the WHO expert committee on selection and use of essential medicines (Including the 21st WHO model list of essential medicines and the 7th WHO model list of essential medicines for children); License: CC BY-NC-SA 3.0 IGO, 2019. Available from: https://apps.who.int/iris/handle/10665/330668 (Accessed on 24 February 2023).
  36. Rugo, H.S.; Linton, K.M.; Cervi, P.; Rosenberg, J.A.; Jacobs, I. A clinician’s guide to biosimilars in oncology. Cancer Treat. Rev., 2016, 46, 73-79. doi: 10.1016/j.ctrv.2016.04.003 PMID: 27135548
  37. Greco, S.; Fabbri, N.; Spaggiari, R.; De Giorgi, A.; Fabbian, F.; Giovine, A. Update on classic and novel approaches in metastatic triple-negative breast cancer treatment: A comprehensive review. Biomedicines, 2023, 11(6), 1772. doi: 10.3390/biomedicines11061772 PMID: 37371867
  38. Shi, M.; Li, Z.; Shen, G.; Wang, T.; Li, J.; Wang, M.; Liu, Z.; Zhao, F.; Ren, D.; Zhao, J. Efficacy and safety of first- line treatment for metastatic triple-negative breast cancer: A network meta-analysis. Cancer Pathogen. Ther., 2023. doi: 10.1016/j.cpt.2023.06.002
  39. Won, K.A.; Spruck, C. Triple-negative breast cancer therapy: Current and future perspectives (Review). Int. J. Oncol., 2020, 57(6), 1245-1261. doi: 10.3892/ijo.2020.5135 PMID: 33174058
  40. Gerratana, L.; Fanotto, V.; Pelizzari, G.; Agostinetto, E.; Puglisi, F. Do platinum salts fit all triple negative breast cancers? Cancer Treat. Rev., 2016, 48, 34-41. doi: 10.1016/j.ctrv.2016.06.004 PMID: 27343437
  41. Garutti, M.; Pelizzari, G.; Bartoletti, M.; Malfatti, M.C.; Gerratana, L.; Tell, G.; Puglisi, F. Platinum salts in patients with breast cancer: A focus on predictive factors. Int. J. Mol. Sci., 2019, 20(14), 3390. doi: 10.3390/ijms20143390 PMID: 31295913
  42. Schmid, P.; Adams, S.; Rugo, H.S.; Schneeweiss, A.; Barrios, C.H.; Iwata, H.; Diéras, V.; Hegg, R.; Im, S.A.; Shaw Wright, G.; Henschel, V.; Molinero, L.; Chui, S.Y.; Funke, R.; Husain, A.; Winer, E.P.; Loi, S.; Emens, L.A. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med., 2018, 379(22), 2108-2121. doi: 10.1056/NEJMoa1809615 PMID: 30345906
  43. Masuda, J.; Ozaki, Y.; Hara, F.; Kitano, S.; Takano, T. Pembrolizumab plus chemotherapy in triple-negative breast cancer. Lancet, 2021, 398(10294), 24. doi: 10.1016/S0140-6736(21)00380-9 PMID: 34217392
  44. Carlino, F.; Diana, A.; Piccolo, A.; Ventriglia, A.; Bruno, V.; De Santo, I.; Letizia, O.; De Vita, F.; Daniele, B.; Ciardiello, F.; Orditura, M. Immune-based therapy in triple-negative breast cancer: From molecular biology to clinical practice. Cancers, 2022, 14(9), 2102. doi: 10.3390/cancers14092102 PMID: 35565233
  45. Mavratzas, A.; Seitz, J.; Smetanay, K.; Schneeweiss, A.; Jäger, D.; Fremd, C. Atezolizumab for use in PD-L1-positive unresectable, locally advanced or metastatic triple-negative breast cancer. Future Oncol., 2020, 16(3), 4439-4453. doi: 10.2217/fon-2019-0468 PMID: 31829043
  46. Schmid, P.; Cortes, J.; Pusztai, L.; McArthur, H.; Kümmel, S.; Bergh, J.; Denkert, C.; Park, Y.H.; Hui, R.; Harbeck, N.; Takahashi, M.; Foukakis, T.; Fasching, P.A.; Cardoso, F.; Untch, M.; Jia, L.; Karantza, V.; Zhao, J.; Aktan, G.; Dent, R.; O’Shaughnessy, J. Pembrolizumab for early triple-negative breast cancer. N. Engl. J. Med., 2020, 382(9), 810-821. doi: 10.1056/NEJMoa1910549 PMID: 32101663
  47. Valenza, C.; Rizzo, G.; Passalacqua, M.I.; Boldrini, L.; Corti, C.; Trapani, D.; Curigliano, G. Evolving treatment landscape of immunotherapy in breast cancer: Current issues and future perspectives. Ther. Adv. Med. Oncol., 2023, 15 doi: 10.1177/17588359221146129 PMID: 36743524
  48. Capici, S.; Ammoni, L.C.; Meli, N.; Cogliati, V.; Pepe, F.F.; Piazza, F.; Cazzaniga, M.E. Personalised therapies for metastatic triple-negative breast cancer: When target is not everything. Cancers, 2022, 14(15), 3729. doi: 10.3390/cancers14153729 PMID: 35954393
  49. Trapani, D.; Ferraro, E.; Giugliano, F.; Boscolo Bielo, L.; Curigliano, G.; Burstein, H.J. Postneoadjuvant treatment for triple-negative breast cancer. Curr. Opin. Oncol., 2022, 34(6), 623-634. doi: 10.1097/CCO.0000000000000893 PMID: 35993306
  50. Catalano, A.; Iacopetta, D.; Ceramella, J.; Mariconda, A.; Rosano, C.; Scumaci, D.; Saturnino, C.; Longo, P.; Sinicropi, M. New achievements for the treatment of triple-negative breast cancer. Appl. Sci., 2022, 12(11), 5554. doi: 10.3390/app12115554
  51. Bravaccini, S.; Maltoni, R. Trop-2 therapy in metastatic triple-negative breast cancer in Italy: Clinical opportunity and regulatory pitfalls. J. Pers. Med., 2021, 11(11), 1211. doi: 10.3390/jpm11111211 PMID: 34834563
  52. Cortesi, M.; Zanoni, M.; Maltoni, R.; Ravaioli, S.; Tumedei, M.M.; Pirini, F.; Bravaccini, S. TROP2 (trophoblast cell-surface antigen 2): A drug target for breast cancer. Expert Opin. Ther. Targets, 2022, 26(7), 593-602. doi: 10.1080/14728222.2022.2113513 PMID: 35962580
  53. Miglietta, F.; Griguolo, G.; Bottosso, M.; Giarratano, T.; Lo Mele, M.; Fassan, M.; Cacciatore, M.; Genovesi, E.; De Bartolo, D.; Vernaci, G.; Amato, O.; Porra, F.; Conte, P.; Guarneri, V.; Dieci, M.V. HER2-low-positive breast cancer: Evolution from primary tumor to residual disease after neoadjuvant treatment. NPJ Breast Cancer, 2022, 8(1), 66. doi: 10.1038/s41523-022-00434-w PMID: 35595761
  54. Schlam, I.; Tolaney, S.M.; Tarantino, P. How I treat HER2-low advanced breast cancer. Breast, 2023, 67, 116-123. doi: 10.1016/j.breast.2023.01.005 PMID: 36669993
  55. Modi, S.; Jacot, W.; Yamashita, T.; Sohn, J.; Vidal, M.; Tokunaga, E.; Tsurutani, J.; Ueno, N.T.; Prat, A.; Chae, Y.S.; Lee, K.S.; Niikura, N.; Park, Y.H.; Xu, B.; Wang, X.; Gil-Gil, M.; Li, W.; Pierga, J.Y.; Im, S.A.; Moore, H.C.F.; Rugo, H.S.; Yerushalmi, R.; Zagouri, F.; Gombos, A.; Kim, S.B.; Liu, Q.; Luo, T.; Saura, C.; Schmid, P.; Sun, T.; Gambhire, D.; Yung, L.; Wang, Y.; Singh, J.; Vitazka, P.; Meinhardt, G.; Harbeck, N.; Cameron, D.A. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med., 2022, 387(1), 9-20. doi: 10.1056/NEJMoa2203690 PMID: 35665782
  56. Zhang, H.; Karakas, C.; Tyburski, H.; Turner, B.M.; Peng, Y.; Wang, X.; Katerji, H.; Schiffhauer, L.; Hicks, D.G. HER2-low breast cancers: Current insights and future directions. Semin. Diagn. Pathol., 2022, 39(5), 305-312. doi: 10.1053/j.semdp.2022.07.003 PMID: 35872032
  57. FDA approves fam-trastuzumab deruxtecan-nxki for HER2-low breast cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-low-breast-cancer (Accessed on 27 February 2023).
  58. Abuhelwa, Z.; Alloghbi, A.; Alqahtani, A.; Nagasaka, M. Trastuzumab deruxtecan-induced interstitial lung disease/pneumonitis in ERBB2-positive advanced solid malignancies: A systematic review. Drugs, 2022, 82(9), 979-987. doi: 10.1007/s40265-022-01736-w PMID: 35759121
  59. Rugo, H.S.; Crossno, C.L.; Gesthalter, Y.B.; Kelley, K.; Moore, H.B.; Rimawi, M.F.; Westbrook, K.E.; Buys, S.S. Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer. JCO Oncol. Pract., 2023, 19(8), 539-546. doi: 10.1200/OP.22.00480 PMID: 37207306
  60. Soares, L.R.; Vilbert, M.; Rosa, V.D.L.; Oliveira, J.L.; Deus, M.M.; Freitas-Junior, R. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: A systematic review and single-arm meta-analysis. ESMO Open, 2023, 8(4), 101613. doi: 10.1016/j.esmoop.2023.101613 PMID: 37481956
  61. Crimini, E.; Tini, G.; Tarantino, P.; Ascione, L.; Repetto, M.; Beria, P.; Ranghiero, A.; Marra, A.; Belli, C.; Criscitiello, C.; Esposito, A.; Guerini Rocco, E.; Barberis, M.C.P.; Mazzarella, L.; Curigliano, G. Evaluation of the geographical accessibility of genome-matched clinical trials on a national experience. Oncologist, 2023, oyad229. doi: 10.1093/oncolo/oyad229 PMID: 37669224
  62. Meattini, I.; Poortmans, P.M.P.; Marrazzo, L.; Desideri, I.; Brain, E.; Hamaker, M.; Lambertini, M.; Miccinesi, G.; Russell, N.; Saieva, C.; Strnad, V.; Visani, L.; Kaidar-Person, O.; Livi, L. Exclusive endocrine therapy or partial breast irradiation for women aged ≥70 years with luminal A-like early stage breast cancer (NCT04134598 – EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures. J. Geriatr. Oncol., 2021, 12(2), 182-189. doi: 10.1016/j.jgo.2020.07.013 PMID: 32739355
  63. Botticelli, A.; Scagnoli, S.; Conte, P.; Cremolini, C.; Ascierto, P.A.; Cappuzzo, F.; Aglietta, M.; Mazzuca, F.; Capoluongo, E.; Blandino, G.; Malapelle, U.; Nuti, M.; D’Amati, G.; Cerbelli, B.; Pruneri, G.; Biffoni, M.; Giannini, G.; Cognetti, F.; Curigliano, G.; Marchetti, P. Molecular landscape and actionable alterations in a genomic-guided cancer clinical trial: First analysis of the ROME trial. J. Clin. Oncol., 2022, 40(16_suppl)(Suppl.), 3087-3087. doi: 10.1200/JCO.2022.40.16_suppl.3087
  64. Gianni, L.; Pienkowski, T.; Im, Y.H.; Roman, L.; Tseng, L.M.; Liu, M.C.; Lluch, A.; Staroslawska, E.; de la Haba-Rodriguez, J.; Im, S.A.; Pedrini, J.L.; Poirier, B.; Morandi, P.; Semiglazov, V.; Srimuninnimit, V.; Bianchi, G.; Szado, T.; Ratnayake, J.; Ross, G.; Valagussa, P. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2- positive breast cancer (NeoSphere): A randomised multicentre, open-label, phase 2 trial. Lancet Oncol., 2012, 13(1), 25-32. doi: 10.1016/S1470-2045(11)70336-9 PMID: 22153890
  65. Bianchini, G.; Kiermaier, A.; Bianchi, G.V.; Im, Y.H.; Pienkowski, T.; Liu, M.C.; Tseng, L.M.; Dowsett, M.; Zabaglo, L.; Kirk, S.; Szado, T.; Eng-Wong, J.; Amler, L.C.; Valagussa, P.; Gianni, L. Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res., 2017, 19(1), 16. doi: 10.1186/s13058-017-0806-9 PMID: 28183321
  66. Lemieux, J.; Clemons, M.; Provencher, L.; Dent, S.; Latreille, J.; Mackey, J.; Pritchard, K.I.; Rayson, D.; Verma, S.; Verma, S.; Wang, B.; Chia, S. The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers. Curr. Oncol., 2009, 16(5), 48-57. doi: 10.3747/co.v16i5.510 PMID: 19862361
  67. Swain, S.M.; Kim, S.B.; Cortés, J.; Ro, J.; Semiglazov, V.; Campone, M.; Ciruelos, E.; Ferrero, J.M.; Schneeweiss, A.; Knott, A.; Clark, E.; Ross, G.; Benyunes, M.C.; Baselga, J. Pertuzumab, trastuzumab, and docetaxel for HER2- positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol., 2013, 14(6), 461-471. doi: 10.1016/S1470-2045(13)70130-X PMID: 23602601
  68. Swain, S.M.; Miles, D.; Kim, S-B.; Im, Y.-H; Im, S.-A.; Semiglazov, V. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): End-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol., 2020, 21, 519-530.
  69. Bachelot, T.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Bondarenko, I.; Paluch-Shimon, S.; Wardley, A.; Merot, J.L.; du Toit, Y.; Easton, V.; Lindegger, N.; Miles, D.; Bouzid, K.; Campone, M.; Coudert, B.; Nowecki, Z.; Errihani, H.; Dalenc, F.; Ferreira, A.; Mano, M.; Ricci, F.; Kalofonos, H.; Andreetta, C.; Montemurro, F.; Barrett, S.; Zhang, Q.; Mavroudis, D.; Matus, J.; Beato, C.; Hu, X.; Gaafar, R.; Abdel Azeem, H.; Perrin, C.; Ettl, J.; Lang, I.; Verma, S.; Li, H.; Brain, E.; Hoffmann, O.; Cariello, A.; Tondini, C.; Altwegeiri, T.; Loman, N.; Lux, M.; Frassoldati, A.; Aziz, Z.; Salas, F.; Streb, J.; Wronski, A.; Menjón Beltrán, S.; Cicin, I.; Schmid, P.; Laing, R.; Tong, Z.; Boer, K.; Juhasz, B.; Gianni, L.; Curigliano, G.; Juarez, A.; Susnjar, S.; Matos, E.; Uslu, R.; Wildiers, H.; Cruz, M.; Bourgeois, H.; von Schumann, R.; Stemmer, S.; Vásquez, F.M.; Dominguez, A.; Wojtukiewicz, M.; Trifunovic, J.; Illarramendi, J.J.; Garcia, L.; Peron, Y.I.; Echarri, M.J.; Voitko, N.; Wheatley, D.; Waters, S.; De Boer, R.; Jerusalem, G.; Cocquyt, V.; Barrios, C.; Panasci, L.; Mattson, J.; Tanner, M.; Gozy, M.; Vasilopoulos, G.; Revesz, J.; Latini, L.; Gridelli, C.; Lazaro, J.; Gonzalez, A.; Barnadas Molins, A.; Martinez, E.; Alarcón, J.; Arance, A.; Klint, L.; Kovalyov, O.; Baird, R.; Yeo, B.; McCarthy, N.; Greil, R.; Wang, S.; Artignan, X.; Augereau, P.; Juhasz-Boess, I.; Ngan, R.; Goldberg, H.; Di Costanzo, F.; Ferraù, F.; Aleknavicius, E.; Rashid, K.; Costa, L.; Angel Garcia, J.; de la Cruz, L.R.; López López, R.; Del Val, O.; Ozyilkan, O.; Azribi, F.; Verrill, M.; Turner, N.; Beith, J.; Petzer, A.; Andrade, J.; Bernstein, V.; Rayson, D.; Saad Eldin, I.; Achille, M.; Mueller, V.; Gennari, A.; Cascinu, S.; Ghosn, M.; El-Saghir, N.; Van den Bosch, J.; Oosterkamp, R.; Kukulska, M.; Pelaez, I.; Hernandez, C.; del Mar Gordon, M.; Dalmau, E.; Alonso, J.L.; Aksoy, S.; Coskun, H.S.; Shparyk, Y.; Varughese, M.; Panwar, U.; Barraclough, L.; Levitt, N.; Hicks, J.; Rigg, A.; Allen, M.; Castillo, C.; Fein, L.E.; Stuart-Harris, R.; Singer, C.; Stoeger, H.; Smiljanic, S.; Feng, J.; Cedeño, M.; Berdah, J.F.; Orfeuvre, H.; Goncalves, A.; Grischke, E-M.; Simon, E.; Wagner, S.; Efremidou, A.; Papazisis, K.; Evron, E.; Inbar, M.; Baruch, N.B.; Geffen, D.; Karminsky, N.; Ruggeri, E.M.; Luigi, C.; Grasso, D.; Juozaityte, E.; Rafael Rodriguez Cid, J.; Roerdink, H.; Siddiqi, N.; Passos Coelho, J.L.; Garre, E.G.; Garcia, A.; Martínez Jañez, N.; Lopez Ceballos, M.H.; Mele, M.; García, M.; Arcediano, A.; McAdam, K.; Perren, T.; Hicks, J.; Taylor, W.; Humphreys, A.; Vera, R.; Kaen, L.A.; Steger, G.; Andel, J.; de Grève, J.; Huizing, M.; Hegg, R.; Joy, A.; Sehdev, S.; Kütner, R.; Ruohola, J.; Dohollou, N.; Grosjean, J.; Laplaige, P.; Largillier, R.; Martin, P.; Pottier, V.; Alexandre, J.; Christensen, B.; Zahm, D-M.; Khandan, F.; Lueck, H-J.; Fountzilas, G.; Fried, G.; Giacobino, A.; Bonetti, A.; Guerra, Y.C.; Van Warmerdam, L.; Van der Velden, A.; Vrijaldenhoven, S.; de Jongh, F.; Cavero, M.; Andres Conejero, R.; Murias, A.; Saura, S.; Oltra, A.; Redondo, A.; Ribelles, N.; Bachmeier, K.; Joffe, J.; Chakraborti, P.; Beresford, M.; Butt, M.; Poole, C.; Yordi, G.; Woodward, N.; Amorim, G.; Califaretti, N.; Fox, S.; Robidoux, A.; Li, N.L.; Li, N.; Jiang, J.; Soria, T.; Padrik, P.; Saarni, O.; Genet, D.; Catala, S.; Barletta, H.; Teixeira, L.; Facchini, T.; Hesse, T.; Kühn, T.; Ober, A.; Repp, R.; Schroeder, W.; Pectasides, D.; Bodoky, G.; Kahan, Z.; Jiveliouk, I.; Rosengarten, O.; Alabiso, O.; Perez, M.; Van de Wouw, Y.; Smok-Kalwat, J.; Damasceno, M.; Sousa, G.; Abulkhair, O.; Antón Torres, A.; Martinez, M.P.; Garcia Mata, J.; Jesús Florián Jerico, M.S.; Llombart, A.; Sanchez, R.; Torrego, J.C.; Garate, C.O.; Rodriguez, C.; Llorente, R.; de Prado, D.S.; Cortés, J.; Llorca, C.; Galán, A.; Viñas Villaro, G.; Narbe, U.; Bjömeklett, H.G.; Westwell, S.; Newby, J.; Jafri, M.; Rodríguez, R.; Alonso, I. Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann. Oncol., 2019, 30(5), 766-773. doi: 10.1093/annonc/mdz061 PMID: 30796821
  70. Miles, D.; Ciruelos, E.; Schneeweiss, A.; Puglisi, F.; Peretz-Yablonski, T.; Campone, M.; Bondarenko, I.; Nowecki, Z.; Errihani, H.; Paluch-Shimon, S.; Wardley, A.; Merot, J.L.; Trask, P.; du Toit, Y.; Pena-Murillo, C.; Revelant, V.; Klingbiel, D.; Bachelot, T.; Bachelot, T.; Bouzid, K.; Campone, M.; Desmoulins, I.; Coudert, B.; Bondarenko, I.; Nowecki, Z.; Glogowska, I.; Ciruelos Gil, E.; Errihani, H.; Dalenc, F.; Ricci, F.; Dieras, V.; Kaufman, B.; Paluch-Shimon, S.; Wardley, A.; Schneeweiss, A.; Ferreira, A.; Mano, M.; Kalofonos, H.; Andreetta, C.; Puglisi, F.; Montemurro, F.; Barrett, S.; Zhang, Q.; Mavroudis, D.; Matus, J.; Villarreal Garza, C.; Beato, C.; Ismael, G.; Hu, X.; Abdel Azeem, H.; Gaafar, R.; Perrin, C.; Kerbrat, P.; Ettl, J.; Paepke, S.; Hitre, E.; Lang, I.; Trudeau, M.; Verma, S.; Li, H.; Hoffmann, O.; Aktas, B.; Cariello, A.; Cruciani, G.; Tienghi, A.; Tondini, C.; Al-Twegieri, T.; Loman, N.; Laing, R.; Miles, D.; Brain, E.; Fasching, P.; Lux, M.; Frassoldati, A.; Aziz, Z.; Salas, J.; Streb, J.; Krzemieniecki, K.; Wronski, A.; Garcia Garcia, J.; Menjon Beltran, S.; Cicin, I.; Schmid, P.; Gallagher, C.; Turner, N.; Tong, Z.; Boer, K.; Juhász, B.; Horvath, Z.; Bianchini, G.; Gianni, L.; Curigliano, G.; Juarez Ramiro, A.; Susnjar, S.; Matos, E.; Sevillano, E.; Garcia Estevez, L.; Gokmen, E.; Uslu, R.; Wildiers, H.; Schutz, F.; Cruz, M.; Bourgeois, H.; von Schumann, R.; Stemmer, S.; Dominguez, A.; Morales-Vásques, F.; Wojtukiewicz, M.; Trifunovic, J.; Echarri Gonzalez, M.J.; Illarramendi Mañas, J.; Martinez De Dueñas, E.; Voitko, N.; Hicks, J.; Waters, S.; Barrett-Lee, P.; Wheatley, D.; De Boer, R.; Cocquyt, V.; Jerusalem, G.; Barrios, C.; Panasci, L.; Mattson, J.; Tanner, M.; Gozy, M.; Vasilopoulos, G.; Papandreou, C.; Revesz, J.; Battelli, N.; Benedetti, G.; Latini, L.; Gridelli, C.; Lazaro Leon, J.; Alarcón Company, J.; Arance Fernandez, A.; Barnadas Molins, A.; Calvo Plaza, I.; Bratos, R.; Gonzalez Martin, A.; Izarzugaza Peron, Y.; Klint, L.; Kovalev, A.; McCarthy, N.; Yeo, B.; Kee, D.; Thomson, J.; White, S.; Greil, R.; Wang, S.; Artignan, X.; Juhasz-Böess, I.; Rody, A.; Ngan, R.; Dourleshter, F.; Goldberg, H.; Doni, L.; Di Costanzo, F.; Ferraù, F.; Drobniene, M.; Aleknavicius, E.; Rashid, K.; Costa, L.; de la Cruz Merino, L.; Garcia Saenz, J.; López, R.; Del Val Munoz, O.; Ozyilkan, O.; Azribi, F.; Jaafar, H.; Baird, R.; Verrill, M.; Beith, J.; Petzer, A.; Moreira de Andrade, J.; Bernstein, V.; Macpherson, N.; Rayson, D.; Saad Eldin, I.; Achille, M.; Augereau, P.; Müller, V.; Rasco, A.; Evron, E.; Katz, D.; Berardi, R.; Cascinu, S.; De Censi, A.; Gennari, A.; El-Saghir, N.; Ghosn, M.; Oosterkamp, H.M.; Van den Bosch, J.; Kukulska, M.; Kalinka, E.; Alonso, J.; Dalmau Portulas, E.; Del Mar Gordon Santiago, M.; Pelaez Fernandez, I.; Aksoy, S.; Altundag, K.; Senol Coskun, H.; Bozcuk, H.; Shparyk, Y.; Barraclough, L.; Hicks, J.; Levitt, N.; Panwar, U.; Kelly, S.; Rigg, A.; Varughese, M.; Castillo, C.; Fein, L.; Malik, L.; Stuart-Harris, R.; Singer, C.; Stoeger, H.; Samonigg, H.; Feng, J.; Cedeño, M.; Ruohola, J.; Berdah, J-F.; Goncalves, A.; Orfeuvre, H.; Grischke, E-M.; Simon, E.; Wagner, S.; Koumakis, G.; Papazisis, K.; Ben Baruch, N.; Fried, G.; Geffen, D.; Karminsky, N.; Peretz, T.; Cavanna, L.; Pedrazzioli, P.; Grasso, D.; Ruggeri, E.; D’Auria, G.; Moscetti, L.; Juozaityte, E.; Rodriguez Cid, J.; Roerdink, H.; Siddiqi, N.; Passos Coelho, J.; Arcediano Del Amo, A.; Garcia Garre, E.; García Gonzalez, M.; Garcia-Palomo Perez, A.; Herenandez Perez, C.; Lopez Alvarez, P.; Lopez De Ceballos, M.H.; Martínez Jañez, N.; Mele Olive, M.; McAdam, K.; Perren, T.; Dunn, G.; Humphreys, A.; Taylor, W.; Vera, R.; Kaen, L.; Andel, J.; Steger, G.; De Grève, J.; Huizing, M.; Hegg, R.; Joy, A.; Kuruvilla, P.; Sehdev, S.; Smiljanic, S.; Kütner, R.; Alexandre, J.; Grosjean, J.; Laplaige, P.; Largillier, R.; Maes, P.; Martin, P.; Pottier, V.; Christensen, B.; Khandan, F.; Lück, H-J.; Zahm, D-M.; Papandreou, C.; Fountzilas, G.; Karavasilis, V.; Safra, T.; Inbar, M.; Ryvo, L.; Bonetti, A.; Seles, E.; Giacobino, A.; Chavarri Guerra, Y.; de Jongh, F.; van der Velden, A.; van Warmerdam, L.; Vrijaldenhoven, S.; Smorenburg, C.H.; Cavero, M.; Andres Conejero, R.; Oltra Ferrando, A.; Redondo Sanchez, A.; Ribelles Entrena, N.; Saura Grau, S.; Viñas Vilaro, G.; Bachmeier, K.; Beresford, M.; Butt, M.; Joffe, J.; Poole, C.; Woodings, P.; Chakraborti, P.; Yordi, G.; Woodward, N.; Nobre, A.; Luiz Amorim, G.; Califaretti, N.; Fox, S.; Robidoux, A.; Li, E.; Li, N.; Jiang, J.; Soria, T.; Padrik, P.; Lahdenpera, O.; Barletta, H.; Dohollou, N.; Genet, D.; Prulhiere, K.; Coeffic, D.; Facchini, T.; Vieillot, S.; Catala, S.; Teixeira, L.; Hesse, T.; Kühn, T.; Ober, A.; Repp, R.; Schröder, W.; Pectasides, D.; Bodoky, G.; Kahan, Z.; Jiveliouk, I.; Rosengarten, O.; Rossi, V.; Alabiso, O.; Pérez Martínez, M.; van de Wouw, A.J.; Smok-Kalwat, J.; Damasecno, M.; Augusto, I.; Sousa, G.; Saadein, A.; Abdelhafiez, N.; Abulkhair, O.; Antón Torres, A.; Corbellas Aparicio, M.; Llorente Domenech, R.; Florián Jerico, J.; Garcia Mata, J.; Gil Raga, M.; Galan Brotons, A.; Llombart Cussac, A.; Llorca Ferrandiz, C.; Martinez Del Prado, P.; Olier Garate, C.; Rodriguez Sanchez, C.; Sanchez Gomez, R.; Santisteban Eslava, M.; Soberino, J.; Vidal Losada Garcia, M.; Soto de Prado, D.; Torrego Garcia, J.; Vicente Rubio, E.; Garcia, M.; Murias Rosales, A.; Granstam Björneklett, H.; Narbe, U.; Jafri, M.; Rea, D.; Newby, J.; Jones, A.; Westwell, S.; Ring, A.; Alonso, I.; Rodríguez, R. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication. Ann. Oncol., 2021, 32(10), 1245-1255. doi: 10.1016/j.annonc.2021.06.024 PMID: 34224826
  71. Schneeweiss, A.; Chia, S.; Hickish, T.; Harvey, V.; Eniu, A.; Waldron-Lynch, M.; Eng-Wong, J.; Kirk, S.; Cortés, J. Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur. J. Cancer, 2018, 89, 27-35. doi: 10.1016/j.ejca.2017.10.021 PMID: 29223479
  72. Squires, H.; Pandor, A.; Thokala, P.; Stevens, J.W.; Kaltenthaler, E.; Clowes, M.; Coleman, R.; Wyld, L. Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: An evidence review group perspective of a NICE single technology appraisal. PharmacoEconomics, 2018, 36(1), 29-38. doi: 10.1007/s40273-017-0556-7 PMID: 28770452
  73. Piccart, M.; Procter, M.; Fumagalli, D.; De Azambuja, E.; Clark, E.; Ewer, M.S. Abstract GS1-04: Interim overall survival analysis of APHINITY (BIG 4-11): A randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable her2-positive early breast cancer. Gen. Sess. Abstr., 2020, 80, GS1-GS04.
  74. Bines, J.; Clark, E.; Barton, C.; Restuccia, E.; Procter, M.; Sonnenblick, A.; Fumagalli, D.; Parlier, D.; Arahmani, A.; Baselga, J.; Viale, G.; Reaby, L.L.; Frank, E.; Gelber, R.D.; Piccart, M.; Jackisch, C.; Petersen, J.A. Patient-reported function, health-related quality of life, and symptoms in APHINITY: Pertuzumab plus trastuzumab and chemotherapy in HER2-positive early breast cancer. Br. J. Cancer, 2021, 125(1), 38-47. doi: 10.1038/s41416-021-01323-y PMID: 33828257
  75. de Azambuja, E.; Agostinetto, E.; Procter, M.; Eiger, D.; Pondé, N.; Guillaume, S.; Parlier, D.; Lambertini, M.; Desmet, A.; Caballero, C.; Aguila, C.; Jerusalem, G.; Walshe, J.M.; Frank, E.; Bines, J.; Loibl, S.; Piccart-Gebhart, M.; Ewer, M.S.; Dent, S.; Plummer, C.; Suter, T. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open, 2023, 8(1), 100772. doi: 10.1016/j.esmoop.2022.100772 PMID: 36681013
  76. Rimawi, M.; Ferrero, J.M.; de la Haba-Rodriguez, J.; Poole, C.; De Placido, S.; Osborne, C.K.; Hegg, R.; Easton, V.; Wohlfarth, C.; Arpino, G. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2–positive and hormone receptor–positive metastatic or locally advanced breast cancer (PERTAIN): A randomized, open-label phase II trial. J. Clin. Oncol., 2018, 36(28), 2826-2835. doi: 10.1200/JCO.2017.76.7863 PMID: 30106636
  77. Bartsch, R. SABCS 2020: Update on triple-negative and metastatic HER2-positive breast cancer. Mag. Eur. Med. Oncol., 2021, 14(3), 247-251. doi: 10.1007/s12254-021-00722-4 PMID: 34221179
  78. Arpino, G.; de la Haba-Rodriguez, J.; Ferrero, J.M.; De Placido, S.; Klingbiel, D.; Revelant, V.; Wohlfarth, C.; Poppe, R.; Rimawi, M.F. Abstract PD3-02: Final analysis of PERTAIN: A randomized, two-arm, open-label, multicenter phase II trial assessing the efficacy and safety of first-line pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in patients with HER2-positive and hormone receptor-positive metastatic or locally advanced breast cancer. Cancer Res., 2021, 81(4_Supplement)(Suppl.), PD3-02. doi: 10.1158/1538-7445.SABCS20-PD3-02
  79. Wildiers, H.; Tryfonidis, K.; Dal Lago, L.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Altintas, S.; Touati, N.; Cardoso, F.; Brain, E. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): An open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group. Lancet Oncol., 2018, 19(3), 323-336. doi: 10.1016/S1470-2045(18)30083-4 PMID: 29433963
  80. Wildiers, H.; Meyskens, T.; Marréaud, S.; Lago, L.D.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Meulemans, B.; Sousa, B.; Poncet, C.; Brain, E. Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer, followed by T-DM1 after progression. Breast, 2022, 64, 100-111. doi: 10.1016/j.breast.2022.05.004 PMID: 35636341
  81. Wildiers, H.; Marreaud, S.; Lago, L.D.; Vuylsteke, P.; Curigliano, G.; Waters, S.; Brouwers, B.; Meulemans, B.; Sousa, B.; Poncet, C.; Brain, E. Abstract P1-18-06: Long term outcome data from the EORTC 75111-10114 ETF/BCG randomized phase II study: Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2- positive metastatic breast cancer, followed by T-DM1 after progression. Cancer Res., 2022, 82(4_Supplement)(Suppl.), P1-18-06. doi: 10.1158/1538-7445.SABCS21-P1-18-06
  82. Hurvitz, S.A.; Martin, M.; Symmans, W.F.; Jung, K.H.; Huang, C.S.; Thompson, A.M.; Harbeck, N.; Valero, V.; Stroyakovskiy, D.; Wildiers, H.; Campone, M.; Boileau, J.F.; Beckmann, M.W.; Afenjar, K.; Fresco, R.; Helms, H.J.; Xu, J.; Lin, Y.G.; Sparano, J.; Slamon, D. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol., 2018, 19(1), 115-126. doi: 10.1016/S1470-2045(17)30716-7 PMID: 29175149
  83. de Haas, S.L.; Slamon, D.J.; Martin, M.; Press, M.F.; Lewis, G.D.; Lambertini, C.; Prat, A.; Lopez-Valverde, V.; Boulet, T.; Hurvitz, S.A. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: An open-label, phase III study (KRISTINE). Breast Cancer Res., 2023, 25(1), 2. doi: 10.1186/s13058-022-01587-z PMID: 36631725
  84. Tolaney, S.M.; Tayob, N.; Dang, C.; Yardley, D.A.; Isakoff, S.J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A.C.; Reeder-Hayes, K.; Rugo, H.S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V.K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A.M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R.C.; Rimawi, M.; Abramson, V.; Pohlmann, P.R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K.; Zheng, Y.; Rosenberg, S.M.; Gelber, R.D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E.P.; Krop, I. Adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT): A randomized clinical trial. J. Clin. Oncol., 2021, 39(21), 2375-2385. doi: 10.1200/JCO.20.03398 PMID: 34077270
  85. Bellon, J.R.; Tayob, N.; Yang, D.D.; Tralins, J.; Dang, C.T.; Isakoff, S.J.; DeMeo, M.; Burstein, H.J.; Partridge, A.H.; Winer, E.P.; Krop, I.E.; Tolaney, S.M. Local therapy outcomes and toxicity from the ATEMPT Trial (TBCRC 033): A phase II randomized trial of adjuvant trastuzumab emtansine versus paclitaxel in combination with trastuzumab in women with stage I HER2-positive breast cancer. Int. J. Radiat. Oncol. Biol. Phys., 2022, 113(1), 117-124. doi: 10.1016/j.ijrobp.2021.12.173 PMID: 34990776
  86. Barroso-Sousa, R.; Tarantino, P.; Tayob, N.; Dang, C.; Yardley, D.A.; Isakoff, S.J.; Valero, V.; Faggen, M.; Mulvey, T.; Bose, R.; Hu, J.; Weckstein, D.; Wolff, A.C.; Reeder-Hayes, K.; Rugo, H.S.; Ramaswamy, B.; Zuckerman, D.; Hart, L.; Gadi, V.K.; Constantine, M.; Cheng, K.; Briccetti, F.; Schneider, B.; Garrett, A.M.; Marcom, K.; Albain, K.; DeFusco, P.; Tung, N.; Ardman, B.; Nanda, R.; Jankowitz, R.C.; Rimawi, M.; Abramson, V.; Pohlmann, P.R.; Van Poznak, C.; Forero-Torres, A.; Liu, M.; Ruddy, K.J.; Zheng, Y.; Rosenberg, S.M.; Gelber, R.D.; Trippa, L.; Barry, W.; DeMeo, M.; Burstein, H.; Partridge, A.; Winer, E.P.; Krop, I.; Tolaney, S.M. Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): A randomized controlled trial. NPJ Breast Cancer, 2022, 8(1), 18. doi: 10.1038/s41523-022-00385-2 PMID: 35173164
  87. Curigliano, G.; Mueller, V.; Borges, V.; Hamilton, E.; Hurvitz, S.; Loi, S.; Murthy, R.; Okines, A.; Paplomata, E.; Cameron, D.; Carey, L.A.; Gelmon, K.; Hortobagyi, G.N.; Krop, I.; Loibl, S.; Pegram, M.; Slamon, D.; Ramos, J.; Feng, W.; Winer, E. Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann. Oncol., 2022, 33(3), 321-329. doi: 10.1016/j.annonc.2021.12.005 PMID: 34954044
  88. Modi, S.; Saura, C.; Yamashita, T.; Park, Y.H.; Kim, S.B.; Tamura, K.; Andre, F.; Iwata, H.; Ito, Y.; Tsurutani, J.; Sohn, J.; Denduluri, N.; Perrin, C.; Aogi, K.; Tokunaga, E.; Im, S.A.; Lee, K.S.; Hurvitz, S.A.; Cortes, J.; Lee, C.; Chen, S.; Zhang, L.; Shahidi, J.; Yver, A.; Krop, I. Trastuzumab deruxtecan in previously treated HER2-positive breast cancer. N. Engl. J. Med., 2020, 382(7), 610-621. doi: 10.1056/NEJMoa1914510 PMID: 31825192
  89. Markham, A. Margetuximab: First approval. Drugs, 2021, 81(5), 599-604. doi: 10.1007/s40265-021-01485-2 PMID: 33761116
  90. MARGetuximab Or Trastuzumab (MARGOT) (MARGOT). 2023. Available from: https://beta.clinicaltrials.gov/study/NCT04425018?tab=results (Accessed on 10 April 2023).
  91. Dang, C.; Ewer, M.S.; Delaloge, S.; Ferrero, J.M.; Colomer, R.; de la Cruz-Merino, L.; Werner, T.L.; Dadswell, K.; Verrill, M.; Eiger, D.; Sarkar, S.; de Haas, S.L.; Restuccia, E.; Swain, S.M. BERENICE final analysis: Cardiac safety study of neoadjuvant pertuzumab, trastuzumab, and chemotherapy followed by adjuvant pertuzumab and trastuzumab in HER2-positive early breast cancer. Cancers, 2022, 14(11), 2596. doi: 10.3390/cancers14112596 PMID: 35681574
  92. Miglietta, F.; Pronzato, P.; Girardi, F.; Griguolo, G.; Guarneri, V.; Pappagallo, G.; Conte, P. Residual risk of relapse: a systematic review and a consensus project on unmet needs for HER2-positive non metastatic breast cancer patients. Eur. J. Cancer, 2022, 175, S57-S58. doi: 10.1016/S0959-8049(22)01504-0
  93. Gluz, O.; Nitz, U.; Liedtke, C.; Christgen, M.; Grischke, E.M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Bangemann, N.; Lindner, C.; Kuemmel, S.; Clemens, M.; Potenberg, J.; Staib, P.; Kohls, A.; von Schumann, R.; Kates, R.; Kates, R.; Schumacher, J.; Wuerstlein, R.; Kreipe, H.H.; Harbeck, N. Comparison of neoadjuvant Nab-Paclitaxel + Carboplatin vs Nab-Paclitaxel + Gemcitabine in triple-negative breast cancer: Randomized WSG-ADAPT-TN trial results. J. Natl. Cancer Inst., 2018, 110(6), 628-637. doi: 10.1093/jnci/djx258 PMID: 29228315
  94. Kolberg-Liedtke, C.; Feuerhake, F.; Garke, M.; Christgen, M.; Kates, R.; Grischke, E.M.; Forstbauer, H.; Braun, M.; Warm, M.; Hackmann, J.; Uleer, C.; Aktas, B.; Schumacher, C.; Kuemmel, S.; Wuerstlein, R.; Graeser, M.; Nitz, U.; Kreipe, H.; Gluz, O.; Harbeck, N. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial. Breast Cancer Res., 2022, 24(1), 58. doi: 10.1186/s13058-022-01552-w PMID: 36056374
  95. Bardia, A.; Hurvitz, S.A.; Tolaney, S.M.; Loirat, D.; Punie, K.; Oliveira, M.; Brufsky, A.; Sardesai, S.D.; Kalinsky, K.; Zelnak, A.B.; Weaver, R.; Traina, T.; Dalenc, F.; Aftimos, P.; Lynce, F.; Diab, S.; Cortés, J.; O’Shaughnessy, J.; Diéras, V.; Ferrario, C.; Schmid, P.; Carey, L.A.; Gianni, L.; Piccart, M.J.; Loibl, S.; Goldenberg, D.M.; Hong, Q.; Olivo, M.S.; Itri, L.M.; Rugo, H.S. ASCENT clinical trial investigators. Sacituzumab govitecan in metastatic triple-negative breast cancer. N. Engl. J. Med., 2021, 384(16), 1529-1541. doi: 10.1056/NEJMoa2028485 PMID: 33882206
  96. Cejuela, M.; Vethencourt, A.; Pernas, S. Immune checkpoint inhibitors and novel immunotherapy approaches for breast cancer. Curr. Oncol. Rep., 2022, 24(12), 1801-1819. doi: 10.1007/s11912-022-01339-4 PMID: 36255603
  97. Nicolò, E.; Tarantino, P.; Curigliano, G. Biology and treatment of HER2-low breast cancer. Hematol. Oncol. Clin. North Am., 2023, 37(1), 117-132. doi: 10.1016/j.hoc.2022.08.013 PMID: 36435605
  98. Fehrenbacher, L.; Cecchini, R.S.; Geyer, C.E., Jr; Rastogi, P.; Costantino, J.P.; Atkins, J.N.; Crown, J.P.; Polikoff, J.; Boileau, J.F.; Provencher, L.; Stokoe, C.; Moore, T.D.; Robidoux, A.; Flynn, P.J.; Borges, V.F.; Albain, K.S.; Swain, S.M.; Paik, S.; Mamounas, E.P.; Wolmark, N. NSABP B-47/NRG oncology phase III randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2+. J. Clin. Oncol., 2020, 38(5), 444-453. doi: 10.1200/JCO.19.01455 PMID: 31821109
  99. Carlino, F.; Diana, A.; Ventriglia, A.; Piccolo, A.; Mocerino, C.; Riccardi, F.; Bilancia, D.; Giotta, F.; Antoniol, G.; Famiglietti, V.; Feliciano, S.; Cangiano, R.; Lobianco, L.; Pellegrino, B.; De Vita, F.; Ciardiello, F.; Orditura, M. HER2-low status does not affect survival outcomes of patients with metastatic breast cancer (MBC) undergoing first-line treatment with endocrine therapy plus palbociclib: Results of a multicenter, retrospective cohort study. Cancers, 2022, 14(20), 4981. doi: 10.3390/cancers14204981 PMID: 36291765
  100. AstraZeneca. A phase 3, randomized, multi-center, open-label study of trastuzumab deruxtecan (T-DXd) versus investigator’s choice chemotherapy in HER2-low, hormone receptor positive breast cancer patients whose disease has progressed on endocrine therapy in the metastatic setting (DESTINY-Breast06). Available from: https://clinicaltrials.gov/ct2/show/NCT04494425 (Accessed on 27 February 2023)
  101. Gombos, A.; Goncalves, A.; Curigliano, G.; Bartsch, R.; Kyte, J.A.; Ignatiadis, M.; Awada, A. How I treat endocrine-dependent metastatic breast cancer. ESMO Open, 2023, 8(2), 100882. doi: 10.1016/j.esmoop.2023.100882 PMID: 36806375
  102. Singh, B.; Olds, T.; Curtis, R.; Dumuid, D.; Virgara, R.; Watson, A.; Szeto, K.; O’Connor, E.; Ferguson, T.; Eglitis, E.; Miatke, A.; Simpson, C.E.M.; Maher, C. Effectiveness of physical activity interventions for improving depression, anxiety and distress: An overview of systematic reviews. Br. J. Sports Med., 2023, 57(18), 1203-1209. doi: 10.1136/bjsports-2022-106195 PMID: 36796860
  103. Cowan, S.; Lim, S.; Alycia, C.; Pirotta, S.; Thomson, R.; Gibson-Helm, M.; Blackmore, R.; Naderpoor, N.; Bennett, C.; Ee, C.; Rao, V.; Mousa, A.; Alesi, S.; Moran, L. Lifestyle management in polycystic ovary syndrome – beyond diet and physical activity. BMC Endocr. Disord., 2023, 23(1), 14. doi: 10.1186/s12902-022-01208-y PMID: 36647089
  104. Catalano, A. COVID-19: Could irisin become the handyman myokine of the 21st century? Coronaviruses, 2020, 1(1), 32-41. doi: 10.2174/2666796701999200617154655
  105. Li, C.; Shang, S.; Liang, W. Physical activity types, physical activity levels and risk of diabetes in general adults: The NHANES 2007–2018. Int. J. Environ. Res. Public Health, 2023, 20(2), 1398. doi: 10.3390/ijerph20021398 PMID: 36674154
  106. Fresno-Alba, S.; Denche-Zamorano, Á.; Pastor-Cisneros, R.; Pereira-Payo, D.; Franco-García, J.M.; Jiménez- Castuera, R. Breast cancer and physical activity: A bibliometric analysis. Front. Oncol., 2023, 12, 1051482. doi: 10.3389/fonc.2022.1051482 PMID: 36713550
  107. Spei, M.E.; Samoli, E.; Bravi, F.; La Vecchia, C.; Bamia, C.; Benetou, V. Physical activity in breast cancer survivors: A systematic review and meta-analysis on overall and breast cancer survival. Breast, 2019, 44, 144-152. doi: 10.1016/j.breast.2019.02.001 PMID: 30780085
  108. Swain, C.T.V.; Drummond, A.E.; Boing, L.; Milne, R.L.; English, D.R.; Brown, K.A.; van Roekel, E.H.; Dixon- Suen, S.C.; Lynch, M.J.; Moore, M.M.; Gaunt, T.R.; Martin, R.M.; Lewis, S.J.; Lynch, B.M. Linking physical activity to breast cancer via sex hormones, part 1: The effect of physical activity on sex steroid hormones. Cancer Epidemiol. Biomarkers Prev., 2022, 31(1), 16-27. doi: 10.1158/1055-9965.EPI-21-0437 PMID: 34670800
  109. De Placido, S.; Giuliano, M.; Schettini, F.; Von Arx, C.; Buono, G.; Riccardi, F.; Cianniello, D.; Caputo, R.; Puglisi, F.; Bonotto, M.; Fabi, A.; Bilancia, D.; Ciccarese, M.; Lorusso, V.; Michelotti, A.; Bruzzese, D.; Veneziani, B.M.; Locci, M.; De Laurentiis, M.; Arpino, G. Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast, 2018, 38, 86-91. doi: 10.1016/j.breast.2017.12.012 PMID: 29287189
  110. Perez, E.A.; López-Vega, J.M.; Petit, T.; Zamagni, C.; Easton, V.; Kamber, J.; Restuccia, E.; Andersson, M. Safety and efficacy of vinorelbine in combination with pertuzumab and trastuzumab for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer: VELVET Cohort 1 final results. Breast Cancer Res., 2016, 18(1), 126. doi: 10.1186/s13058-016-0773-6 PMID: 27955684
  111. Alam, M.M.; Rahman, T.; Afroz, Z.; Chakraborty, P.A.; Wahab, A.; Zaman, S.; Hawlader, M.D.H. Quality of Life (QoL) of cancer patients and its association with nutritional and performance status: A pilot study. Heliyon, 2020, 6(10), e05250. doi: 10.1016/j.heliyon.2020.e05250 PMID: 33134577
  112. Sprangers, M.A.; Groenvold, M.; Arraras, J.I.; Franklin, J.; te Velde, A.; Muller, M.; Franzini, L.; Williams, A.; de Haes, H.C.; Hopwood, P.; Cull, A.; Aaronson, N.K. The european organization for research and treatment of cancer breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. J. Clin. Oncol., 1996, 14(10), 2756-2768. doi: 10.1200/JCO.1996.14.10.2756 PMID: 8874337
  113. Giesinger, J.M.; Loth, F.L.C.; Aaronson, N.K.; Arraras, J.I.; Caocci, G.; Efficace, F.; Groenvold, M.; van Leeuwen, M.; Petersen, M.A.; Ramage, J.; Tomaszewski, K.A.; Young, T.; Holzner, B. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. J. Clin. Epidemiol., 2020, 118, 1-8. doi: 10.1016/j.jclinepi.2019.10.003 PMID: 31639445
  114. Iacopetta, D.; Ceramella, J.; Catalano, A.; Saturnino, C.; Pellegrino, M.; Mariconda, A.; Longo, P.; Sinicropi, M.S.; Aquaro, S. COVID-19 at a glance: An up-to-date overview on variants, drug design and therapies. Viruses, 2022, 14(3), 573. doi: 10.3390/v14030573 PMID: 35336980
  115. Bjelic-Radisic, V.; Cardoso, F.; Cameron, D.; Brain, E.; Kuljanic, K.; da Costa, R.A.; Conroy, T.; Inwald, E.C.; Serpentini, S.; Pinto, M.; Weis, J.; Morag, O.; Lindviksmoen Astrup, G.; Tomaszweksi, K.A.; Pogoda, K.; Sinai, P.; Sprangers, M.; Aaronson, N.; Velikova, G.; Greimel, E.; Arraras, J.; Bottomley, A.; Bleiker, E.; Bliem, B.; Chie, W.; Creutzberg, C.; Deville, V.; Duhoux, F.; Eilf, K.; Hartup, S.; Koller, M.; Nagele, E.; Nicolatou-Galitis, O.; Oberguggenberger, A.; Schmalz, C.; Winters, Z. An international update of the EORTC questionnaire for assessing quality of life in breast cancer patients: EORTC QLQ-BR45. Ann. Oncol., 2020, 31(2), 283-288. doi: 10.1016/j.annonc.2019.10.027 PMID: 31959345
  116. Chiesi, F.; Vizza, D.; Valente, M.; Bruno, R.; Lau, C.; Campagna, M.R.; Lo Iacono, M.; Bruno, F. Positive personal resources and psychological distress during the COVID-19 pandemic: Resilience, optimism, hope, courage, trait mindfulness, and self-efficacy in breast cancer patients and survivors. Support. Care Cancer, 2022, 30(8), 7005-7014. doi: 10.1007/s00520-022-07123-1 PMID: 35579755
  117. Adams-Campbell, L.L.; Hicks, J.; Makambi, K.; Randolph-Jackson, P.; Mills, M.; Isaacs, C.; Dash, C. An 8-week exercise study to improve cancer treatment related fatigue and QOL among African American breast cancer patients undergoing radiation treatment: A pilot randomized clinical trial. J. Natl. Med. Assoc., 2023, 115(2), 199-206. doi: 10.1016/j.jnma.2023.01.011 PMID: 36828705
  118. Cariolou, M.; Abar, L.; Aune, D.; Balducci, K.; Becerra- Tomás, N.; Greenwood, D.C.; Markozannes, G.; Nanu, N.; Vieira, R.; Giovannucci, E.L.; Gunter, M.J.; Jackson, A.A.; Kampman, E.; Lund, V.; Allen, K.; Brockton, N.T.; Croker, H.; Katsikioti, D.; McGinley-Gieser, D.; Mitrou, P.; Wiseman, M.; Cross, A.J.; Riboli, E.; Clinton, S.K.; McTiernan, A.; Norat, T.; Tsilidis, K.K.; Chan, D.S.M. Postdiagnosis recreational physical activity and breast cancer prognosis: Global cancer update programme (CUP global) systematic literature review and meta-analysis. Int. J. Cancer, 2023, 152(4), 600-615. doi: 10.1002/ijc.34324 PMID: 36279903
  119. Murri, A.; Vitucci, D.; Tranchita, E.; Grazioli, E.; Gori, S.; Modena, A.; Turazza, M.; Filippini, R.; Galeazzi, S.; Verzè, M.; Frittelli, P.; Corsi, D.C.; Nicolis, F.; Parisi, A.; Cerulli, C. "OPERATION PHALCO" Adapted physical activity for breast cancer survivors: Is it time for a multidisciplinary approach? Cancers, 2022, 15(1), 34. doi: 10.3390/cancers15010034 PMID: 36612031

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers